/** blogpostTitle: Anlon in Q1 FY27: Scale Up First, Margins Later blogpostSlug: anlon-q1fy27 blogpostCoverImageUrl: null blogpostCoverImageDescription: An ultra-realistic corporate finance scene showing a clean desk with a laptop displaying a dashboard-style line chart of consolidated revenue rising sharply from FY24 to FY26 and another bar chart comparing Q1 FY26 versus Q1 FY27 revenue, alongside a separate chart showing EBITDA margin dipping in Q1 FY27. In the background, a subtle factory silhouette and chemical lab glassware are visible as blurred elements to represent APIs and intermediates, with neutral lighting and a professional boardroom aesthetic. No logos or text labels. blogpostShortTitle: Anlon Q1 FY27 scale and margin reset */

Anlon in Q1 FY27: Scale Up First, Margins Later

Anlon Healthcare Limited entered FY27 with a quarter that looked very different from the year before. On a consolidated basis, Q1 FY27 revenue rose to INR 87.56 crore from INR 33.30 crore in Q1 FY26. Total income was INR 87.62 crore versus INR 33.31 crore. EBITDA increased to INR 15.65 crore from INR 6.26 crore, and profit after tax increased to INR 8.28 crore from INR 3.55 crore.

But the quarter also came with a trade-off. Consolidated EBITDA margin moderated to 17.86% in Q1 FY27 from 18.78% in Q1 FY26. In the earnings call, Managing Director Punitkumar Rasadia attributed this primarily to a sharp increase in certain raw material prices due to geopolitical disruption, and to the consolidation of expenses from Remember India Health Links, which the company acquired in May 2026 and described as being in an investment and turnaround phase.

This set the tone for the quarter. Anlon is in the middle of transforming from an API and intermediates-focused company into a broader platform spanning intermediates, APIs, custom manufacturing, finished dosage formulations, and industrial and fine chemicals. Q1 FY27 showed the first real financial footprint of that transition.

A quarter defined by consolidation and integration

Management was clear that Q1 FY27 was not just a higher revenue quarter. It was a structurally different business compared to the same quarter last year, largely because of the consolidation of subsidiaries acquired over FY26 and early FY27.

During the call, management shared a Q1 FY27 revenue split by entity:

• Anlon standalone operations contributed around INR 32 crore
• Apiqo Organics contributed around INR 45 crore
• Bizotic Lifescience contributed around INR 12 crore

Apiqo and Bizotic are positioned as operational platforms that added capacity and improved the group’s cost and supply security. Remember India Health Links is positioned differently: it provides entry into finished dosage formulations and access to formulation dossiers, but management expects limited contribution until later in the year.

The company’s investor presentation frames these moves as transformational acquisitions. Apiqo Organics was acquired for a 67.48% stake (cash consideration INR 5.40 crore), Bizotic Lifescience for a 56.67% stake (cash consideration INR 3.79 crore), and Remember India Health Links for a 63.98% stake (acquisition value INR 5.38 crore; completed 8 May 2026).

Anlon’s rationale has been consistent across the deck and the call. Apiqo strengthens backward integration and is also tied to the company’s industrial and fine chemicals initiative. Bizotic provides a ready-to-operate facility and faster capacity buildout versus a greenfield project. Remember India expands the company across the pharma value chain into formulations.

Segment mix shifted, and APIs took a bigger share

The standalone segment mix shown in the presentation indicates a clear shift in Q1 FY27. APIs contributed 50.32% of standalone revenue in Q1 FY27, up from 22.17% in Q1 FY26. Pharmaceutical intermediates contributed 43.93%, down from 73.42%. Nutraceuticals were 5.58% in Q1 FY27 versus 4.17% in Q1 FY26. Others were 0.17% in Q1 FY27.

The full-year picture also shows a significant mix change. In FY26, APIs contributed 71.24% of revenue (standalone), while pharmaceutical intermediates contributed 26.37%, nutraceuticals 1.93% and others 0.46%. In FY25, APIs were 58.13% and intermediates 35.70%, with nutraceuticals at 6.16%.

The implication is that Anlon has moved toward a more API-heavy mix over the last year, at least on a standalone basis, even as it adds new business lines via subsidiaries. This matters because the company’s strategy also leans on regulatory filings and regulated-market penetration.

Financial summary (Consolidated)

The margin story: cost shock plus a new subsidiary in turnaround

The company’s Q1 FY27 margin compression came with an unusually direct explanation. Management said raw material prices linked to petrochemical solvents rose sharply, giving a specific example of methanol moving from around INR 22 to INR 58-60. The management also said it is difficult to change customer pricing daily in a B2B model, so part of the cost shock hits margins until price revisions flow through.

The second component was structural. After the acquisition of Remember India Health Links, its operating expenses are consolidated into group financials. Management stated it is currently in an investment and turnaround phase, and that it weighed on near-term consolidated margins.

Despite this, management maintained that margins should recover. On the call, management said it expects EBITDA margins to gradually recover and work toward stabilizing them in the 25% to 30% range during Q2 and Q3 of FY27. In subsequent answers, it also indicated confidence of delivering 25% to 27% EBITDA margin for FY27.

Capacity platform and regulatory pipeline remain central to the plan

Anlon’s presentation states installed capacity of 1,400 to 1,600 MTPA, with consolidated utilization at 62.37%. The company also highlights operational infrastructure such as two dedicated blocks for APIs and intermediates, and reactors ranging from 20L to 200L assemblies.

On the regulatory front, the company states it has filed 21 DMFs. It also mentions specific regulatory milestones including:

• CEP approval from EDQM (Europe) for Ketoprofen
• Filing with ANVISA (Brazil) for Loxoprofen sodium dihydrate
• Filing with NMPA (China) for Loxoprofen sodium dihydrate

The presentation also states that DMF submissions are in progress for Ketoprofen in the USA and Dexketoprofen Trometamol in key European jurisdictions, and that approvals are expected in a couple of years.

Management further indicated it plans to file seven new DMFs within FY27 and that the company intends to launch seven new APIs in FY26-27 across additional therapeutic categories.

What management guided for FY27 and beyond

The most explicit financial guidance came in the Q&A. Management stated it expects FY27 revenue in the range of INR 350 to 400 crore. This is higher than what an annualized Q1 run-rate suggests, but management advised investors not to rely on quarter annualization due to long production cycle times for certain products.

For FY28, management stated it expects revenue around INR 700 crore if the Anlon site expansion is completed on schedule. It also clarified that the new capacity would not be ramped at 100% immediately, and it is considering 50% to 60% utilization for initial projections.

The capex plan disclosed on the call was:

• Around INR 130 crore expansion capex at the Anlon site
• Around INR 70 crore to be funded through debt
• Remaining to be funded from internal sources

The company also discussed its financing cost expectations for this debt at around 8.5% to 8.6%.

On profitability, management guided PAT margin around 12% to 13% for FY27 and FY28, describing it as conservative given execution and approval timelines.

Takeaways from Q1 FY27

Q1 FY27 showed the shape of Anlon’s new consolidated business. Scale increased sharply, driven by acquisitions that brought manufacturing platforms into the group. At the same time, the quarter made clear that integration comes with near-term margin pressure, especially when combined with a sharp input-cost shock.

The year now hinges on three measurable outcomes that management has discussed openly: execution on price revisions to restore margins, progress on integrating and activating Remember India Health Links, and delivery of the INR 130 crore expansion timeline targeted around Q1 FY28.

If management executes within these timeframes, the company’s guidance of INR 350 to 400 crore revenue in FY27 and a higher FY28 run-rate becomes easier to underwrite. But investors will likely keep a close watch on margins and working capital discipline as the platform scales.